Ms Carell has an extensive background in operating, acquiring and developing healthcare and life science companies. She has previously held the position as CEO of Exeltis USA Inc., the branded division of pharmaceutical company Chemo Group, which she joined in 2014. Prior to this she was President of Meda US and Executive Vice President of Meda North America & South Pacific at Meda Inc. Before joining Meda, she served as President and CEO of Q-Med AB, a global medical device company, which was acquired by Galderma in 2011 for approx. $1 billion.
Prior to Q-Med, Ms Carell worked as General Manager at Actavis Pharmaceuticals in the Nordic region. She has also served in several Business Development, Sales and Marketing roles for organizations ranging in size from small entrepreneurial to large cap global (Novartis, Johnson & Johnson).
Ms Carell has also held several board assignments as Board Member and as Chair of the Board in both public and private life science and health care provider companies.
Ms Furberg has more than 30 years of experience in the pharmaceutical industry. She is currently Senior Vice President Rare Disease EMEA at Sanofi Genzyme, which she joined in 2002. She opened the first operation for Genzyme in the Nordic region and has also had responsibility for Genzyme in the Benelux region. Prior to Genzyme, Ms Furberg spent 15 years at Baxter in various business roles of increasing seniority, before which she was involved in the start-up of Pharmalink. She is currently chairperson at BerGenBio and has held board memberships at Algeta ASA, Clavis Pharma ASA, Pronova Biopharma ASA, Probi AB and Copenhagen Capacity. She holds a Master of Science degree in Chemistry from the University of Oslo.
Mr Julander has extensive experience as an entrepreneur in the pharmaceutical and medical technology industries as well as in private equity. He is a member of the boards of several listed and private companies in the life sciences sector, including as Chairman of Medcap AB, Director of Stille AB, Sedana Medical AB, Unimedic AB, Proequo AB and nWise AB. Mr Julander is a founder of Pharmalink and was Chairman from 1991-2009 after which he remained as a Director on the board of the company.
Mr Hellebø is CEO of UK-listed ReNeuron Group plc, and chairman and co-founder of Palma Biotech S.L. in Spain. He is an experienced pharmaceutical executive who has held senior positions in the pharmaceutical industry in both Europe and the USA. Previously Mr Hellebø was CEO of Clavis Pharma ASA and before that he was Senior Vice President, UCB Pharma and President of Immunology Operations. In this position he built and led the global organization responsible for the successful registration and launch of Cimzia®, UCB’s antibody drug for the treatment of rheumatoid arthritis and Crohn’s disease. From 2003 to 2004, Mr Hellebø was Chief Operating Officer of Novartis UK and prior to that held a series of senior international roles at Schering Plough, the last as head of Schering Plough’s Oncology Biotech Division in the USA. Mr Hellebø graduated Summa cum Laude in international business studies from Hofstra University, New York and received an MBA from IESE, Barcelona.
Ms Kongsnes is an Investment Director at Investinor, Norway’s largest investor in venture and expansion capital and an investor in Pharmalink. She holds an MSc in Economics and Business Administration from Bodø College (HiB) and the Advanced Program in Corporate Finance at the Norwegian School of Economics (NHH). She was previously an investment manager at ProVenture Managment AS, Business Development Manager at Leiv Eiriksson Nyskaping AS, Director of Marketing & Operations at NSEC Inc. and Marketing Manager at the Norwegian Seafood Export Council. In addition to Pharmalink, Ms is a board member of Investinor’s portfolio companies Ayanda AS, Nordic Seafarms AS, poLight AS, and Soundrop AS. She is also deputy board member at BerGenBio AS and head of International Affairs at Investinor.